The Journal of thoracic and cardiovascular surgery · 2025
Replacement of the superior vena cava by the bovine pericardium conduit: Sustained patency without long-term anticoagulation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Argento Giacomo, Rendina Erino Angelo, D'Andrilli Antonio, Ciccone Anna Maria, Ibrahim Mohsen, Trabalza Marinucci Beatrice, Venuta Federico, Maurizi Giulio
Аннотация
OBJECTIVES: Direct infiltration of the superior vena cava by thoracic malignancies often requires en bloc resection and vascular reconstruction. Synthetic grafts such as polytetrafluoroethylene are associated with thrombosis and long-term anticoagulation. We present a large experience with bovine pericardium conduits for superior vena cava replacement, focusing on durable patency without long-term anticoagulation.
METHODS: Between 2003 and 2024, 61 patients with superior vena cava infiltration underwent replacement with a bovine pericardium conduit. Indications included lung cancer (40 cases) and thymic tumors (21 cases). Vascular reconstruction was performed using crossclamping without shunt. Postoperative follow-up included regular imaging studies (computed tomography and magnetic resonance imaging) to assess conduit patency and clinical outcomes.
RESULTS: All patients achieved complete R0 resection. No long-term anticoagulation therapy was required postoperatively. Follow-up imaging confirmed long-term conduit patency in all surviving patients over 1 to 5 years, except 1 patient with jugular vein thrombosis secondary to a port-a-cath. The 30-day mortality rate was 6.5% (4 patients), with no deaths due to vascular complications. Major complications occurred in 9.8% of cases. For thymic tumors, the 5-year survival was 53.7%, whereas for lung cancer, it was 38.8%.
CONCLUSIONS: Bovine pericardium conduits offer a safe and effective option for superior vena cava replacement, providing excellent prolonged patency without long-term anticoagulation. This biological material reduces the risks associated with synthetic grafts, representing a valuable alternative in complex vascular reconstructions. Broader adoption could significantly improve outcomes for patients undergoing superior vena cava replacement.
METHODS: Between 2003 and 2024, 61 patients with superior vena cava infiltration underwent replacement with a bovine pericardium conduit. Indications included lung cancer (40 cases) and thymic tumors (21 cases). Vascular reconstruction was performed using crossclamping without shunt. Postoperative follow-up included regular imaging studies (computed tomography and magnetic resonance imaging) to assess conduit patency and clinical outcomes.
RESULTS: All patients achieved complete R0 resection. No long-term anticoagulation therapy was required postoperatively. Follow-up imaging confirmed long-term conduit patency in all surviving patients over 1 to 5 years, except 1 patient with jugular vein thrombosis secondary to a port-a-cath. The 30-day mortality rate was 6.5% (4 patients), with no deaths due to vascular complications. Major complications occurred in 9.8% of cases. For thymic tumors, the 5-year survival was 53.7%, whereas for lung cancer, it was 38.8%.
CONCLUSIONS: Bovine pericardium conduits offer a safe and effective option for superior vena cava replacement, providing excellent prolonged patency without long-term anticoagulation. This biological material reduces the risks associated with synthetic grafts, representing a valuable alternative in complex vascular reconstructions. Broader adoption could significantly improve outcomes for patients undergoing superior vena cava replacement.